Attovia Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Attovia Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- ATTO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002058707
Board of directors
-
Aaron Royston · DirectorSince 2026
-
Angie You · DirectorSince 2026
-
Colin Walsh · DirectorSince 2026
-
James N. Topper · DirectorSince 2026
-
John W. Smither · DirectorSince 2026
-
Mitchell Gold · DirectorSince 2026
Board connections
4 of this board's directors also sit on 6 other boards.
- via James N. Topper and John W. Smither
- via Aaron Royston
- via James N. Topper
- via John W. Smither
- via Angie You
- via James N. Topper
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $52,369,979
- 9 purchases by 6 insiders
- Sold, last 12 months
- $4,503,315
- 46 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. 10% owner | Derivative conversion | +1,749,192 | — | — |
| Aug 6, 2026 | Redmile Group, LLC 10% owner | Derivative conversion | +782,854 | — | — |
| Aug 6, 2026 | Sanofi 10% owner | Derivative conversion | +782,855 | — | — |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. 10% owner | Derivative conversion | +2,311,870 | — | — |
| Aug 6, 2026 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Derivative conversion | +1,957,138 | — | — |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. 10% owner | Derivative conversion | +1,590,175 | — | — |
| Aug 6, 2026 | Redmile Group, LLC 10% owner | Open-market purchase | +200,000 | $17.00 | $3,400,000 |
| Aug 6, 2026 | Sanofi 10% owner | Open-market purchase | +300,000 | $17.00 | $5,100,000 |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. 10% owner | Derivative conversion | +821,998 | — | — |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. 10% owner | Derivative conversion | +1,189,940 | — | — |
| Aug 6, 2026 | Redmile Group, LLC 10% owner | Open-market purchase | +400,000 | $17.00 | $6,800,000 |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. 10% owner | Derivative conversion | +665,147 | — | — |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. 10% owner | Derivative conversion | +961,322 | — | — |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P. 10% owner | Open-market purchase | +382,352 | $17.00 | $6,499,984 |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P. 10% owner | Open-market purchase | +588,235 | $17.00 | $9,999,995 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.